SIBN (SI-BONE Corp) Market Value to Book Value Ratio

SI-BONE Corp (SIBN) - corporate logo

SI-BONE, Inc. (SIBN) dominates the narrow sacroiliac joint implantation segment due to patent protection and the complexity of physician retraining. Monetization relies on FDA approval and Medicare reimbursement rates, ensuring absolute surgeon loyalty. The visualization of market value, where the indicator reaches 5.29, confirms its leadership status. The brand's impeccable authority and the proven effectiveness of the iFuse system make the company a benchmark in its field.

Market Capitalization to Net Assets: SI-BONE Medical (SIBN) for 07/04/2022 - 10/28/2026
Finished products of SI-BONE Inc

To filter for high-quality assets, investors compare the market value of a business with its tangible capital. By analyzing the price-to-book history on GURU.Markets, one can assess the premium paid for the unique implant technologies of SI-BONE (SIBN), where the ratio of share price to net assets reflects the market premium for the company's strong reputation among surgeons and the efficiency of its production capacities.

Direct competitors

Market Value to Book Value Ratio Boston Scientific|EW (edwards.com) - Capitalization to Book Value Ratio|RMD: Market Value to Book Value Ratio|Market Capitalization to Book Value PODD|ZBH - Market Value to Book Value Ratio|Market Capitalization to Net Assets CooperSurgical (COO)|ALGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio globusmedical.com GMED|TMDX: Market Capitalization to Book Value Ratio|ATEC - Market Cap to Net Assets Ratio|Artivion Inc - Market Capitalization to Book Value Ratio|Enovis Inc. (ENOV) - Market Capitalization to Book Value|IART (Integra LifeSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ESTA|Market Value to Book Value Ratio Beta Bionics (BBNX)|Market Value to Book Value Ratio IRADIMED Corp (IRMD)|Market Capitalization to Book Value Ratio EMBC|TNDM - Market Capitalization to Book Value|Market Cap to Net Assets Ratio AxoGen, Inc.|OFIX - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio BVS|OrthoPediatrics (KIDS) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Treace Medical (TMCI)|Capitalization to Book Value Ratio Strata Medical (SRTA)|Carlsmed Inc (CARL) - Market Cap to Net Assets Ratio|Market Value to Book Value RXST (rxsight.com)|ClearPoint Neuro - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Stereotaxis Inc STXS|STIM (NeuroStar) - Market Capitalization to Book Value Ratio|SGHT - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Orchestra BioMed|Anika Therapeutics, Inc. (ANIK) - Capitalization to Book Value Ratio|NSPR: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Jin Medical International Ltd|Market Capitalization to Book Value Ratio VANI (Vivani Medical, Inc.)|Market Cap to Net Assets Ratio xtantmedical.com (XTNT)|Market Capitalization to Book Value Ratio NMTC (NeuroOne Medical Technologies)|Modular Medical Inc - Market Capitalization to Book Value Ratio|MYO - Market Value to Book Value Ratio|Envoy Medical Inc. (COCH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Vivos Therapeutics, Inc VVOS|enVVeno Corp (NVNO) - Market Value to Book Value|Market Capitalization to Book Value Ratio SINT (Sintx Technologies Inc)|Market-to-Book Ratio TNON|LFWD: Market Value to Book Value Ratio|Market Value to Equity Ratio autonomix.com AMIX|Market Cap to Net Assets Ratio IVF (INVO Bioscience, Inc.)|Market Capitalization to Book Value Ratio Bone Biologics Inc BBLG|Market Capitalization to Book Value Ratio AXNX (Axonics, Inc.)|BIOL: Market Capitalization to Book Value|Market Value to Book Value Ratio dynatronics.com (DYNT)|FNA (Paragon 28) - Market Capitalization to Net Assets|Market Value to Book Value Ratio INVO